Pharma Stocks in Focus: Key Developments on September 25

Ipca Laboratories has forged a strategic partnership with BioSimilar Sciences PR LLC (BSS) to advance a next-generation monoclonal antibody biosimilar targeting cancer and autoimmune diseases. The collaboration will see Ipca transfer late-stage development, clinical manufacturing, and commercial supply to BSS's 200,000 sq. ft facility in Puerto Rico.

Lupin has secured tentative approval from the US health regulator for its generic version of Bictegravir, Emtricitabine, and Tenofovir Alafenamide tablets, a critical treatment for HIV infection. This milestone underscores Lupin's growing footprint in the competitive generics market.

Glenmark Pharmaceuticals' subsidiary, Glenmark Specialty SA, has inked an exclusive licensing deal with Hengrui Pharma for the global development and commercialization of Trastuzumab Rezetecan, a promising cancer treatment. The agreement excludes certain regions, with Glenmark paying an $18 million upfront fee and potential milestone payments reaching $1.093 billion.

Poly Medicure is expanding its portfolio through the acquisition of Medistream SA, including Citieffe SRL and its subsidiaries in the US and Mexico. This MOVE signals Poly Medicure's aggressive growth strategy in the medical devices sector.